Shanghai Rongcan Shikang Life Technology
Committed to the development and industrialization of nucleic acid drugs
About Shanghai Rongcan Shikang Life Technology
RongCan Biotech is a pioneering company in the field of nucleic acid-based medicines, leveraging proprietary RNA and lipid nanoparticle (LNP) technologies to develop innovative treatments for various human diseases. The company operates in the biotechnology and pharmaceutical markets, focusing on the prevention and treatment of diseases by regulating target gene expression and protein function. RongCan Biotech serves a diverse range of clients, including hospitals, infectious disease prevention and control units, scientific research institutes, and contract research organizations (CROs). The business model is centered around the development and commercialization of its proprietary RNA-based Therapeutic Platform (RTP), which includes LNP-based mRNA and siRNA delivery systems. These systems are designed to offer optimal safety and efficacy profiles, making them highly attractive for clinical applications. RongCan Biotech generates revenue through strategic collaborations, product development partnerships, and clinical cooperation agreements. The company is led by a team of scientists and engineers with extensive expertise in mRNA and LNP technologies, many of whom have trained at prestigious institutions such as MIT and Harvard Medical School. The company is committed to achieving win-win situations through cooperation with various stakeholders in the healthcare and scientific communities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2023 | $14M | $55M | Beijing Huafang Investment · Yuexiu Industrial Fund · Shaanxi Investment Growth Fund · Zhangjiagang Jintai Jinhong Fund | ↗ |
| EARLY VC✓Equity / VC | Nov 2022 | $2.8M | $11M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Shanghai Rongcan Shikang Life Technology is 450 monthly website visits, down 23.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Rongcan Shikang Life Technology in its local ecosystem
The Shanghai Rongcan Shikang Life Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- BIBeijing Huafang Investment
- YFYuexiu Industrial Fund
- SFShaanxi Investment Growth Fund
- ZFZhangjiagang Jintai Jinhong Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Rongcan Shikang Life Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Rongcan Shikang Life Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








